Cancer Letters
Volume 291, Issue 2 , Pages 167-176 , 28 May 2010

MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: Synergistic action with LY294002, an inhibitor of phosphatidylinositol 3′-kinase

  • Sivalokanathan Sarveswaran

      Affiliations

    • Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI 48202, United States
    • ,
  • Charles E. Myers

      Affiliations

    • American Institute for Diseases of the Prostate, Charlottesville, VA, United States
    • ,
  • Jagadananda Ghosh

      Affiliations

    • Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI 48202, United States
    • Corresponding Author InformationCorresponding author. Address: Henry Ford Health System, 1 Ford Place, 2D, Detroit, MI 48202, United States. Tel.: +1 313 874 4786.

Received 8 September 2009 ,Revised 7 October 2009 ,Accepted 13 October 2009.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin. 2007;57:43–66
  2. Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J. Urol. 2004;171:19–24
  3. Kolonel LN, Nomura AN, Cooney RV. Dietary fat and prostate cancer: current status. J. Natl. Cancer Inst. 1999;91:414–428
  4. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 1995;87:1456–1462
  5. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 1997;235:418–423
  6. Ghosh J, Myers CE. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol. 1999;469:577–582
  7. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, Alrefai W, et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate. 1998;37:161–173
  8. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA. 1998;95:13182–13187
  9. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274
  10. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006;7:606–619
  11. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 1997;22:355–358
  12. Altomare DA, Testa JR. Perturbations of the Akt signaling pathway in human cancer. Oncogene. 2005;24:7455–7464
  13. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005;4:988–1004
  14. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, et al. The LNCaP cell line—a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 1980;37:115–132
  15. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998;58:2720–2723
  16. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res. 1999;59:1449–1453
  17. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase–activating protein. Science. 2007;317:510–512
  18. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What’s all the FLAP about? 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 2008;29:72–78
  19. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27:6245–6251
  20. Ghosh J. Targeting 5-lipoxygenase for prevention and treatment of cancer. Curr. Enzyme Inhib. 2008;4:18–28
  21. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer. 2001;91:737–743
  22. Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int. J. Oncol. 2004;24:821–827
  23. Moretti RM, Montagnani MM, Sala A, Motta M, Limonta P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int. J. Cancer. 2004;112:87–93
  24. Yang P, Collin P, Madden T, Sweeney-Gotsch B, McConkey D, Newman RA. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate. 2003;55:281–291
  25. Pham H, Vang K, Ziboh VA. Dietary gamma-linolenate attenuates tumor growth in a rodent model of prostatic adenocarcinoma via suppression of elevated generation of PGE(2) and 5S-HETE. Prostagland. Leukotr. Essent. Fatty Acids. 2006;74:271–282
  26. Ochoa JJ, Farquharson AJ, Grant I, Moffat LE, Heys SD, Wahle SKW. Conjugated linoleic acids (CLAs) decrease prostate cancer cell proliferation: different molecular mechanisms for cis-9, trans-11 and trans-10, cis-12 isomers. Carcinogenesis. 2004;25:1185–1191
  27. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 1994;369:156–160
  28. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK-1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025–1037
  29. Yu R, Jiao JJ, Duh JL, Tan TH, Kong AN. Phenethyl isothiocyanate, a natural chemopreventive agent, activates c-Jun N-terminal kinase 1. Cancer Res. 1996;56:2954–2959
  30. Brunet A, Pouyssegur J. Identification of MAP kinase domains by redirecting stress signals into growth factor responses. Science. 1996;272:1652–1655
  31. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J. Biol. Chem. 1996;271:24313–24316
  32. Maroney AC, Finn JP, Bozyczko-Coyne D, O’Kane TM, Neff NT, Tolkovsky AM, et al. CEP-1347 (KT 7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J. Neurochem. 1999;73:1901–1912
  33. Keith S, Abayasiriwardana D, Barbone D, Kim KU, Vivo C, Lee KK, et al. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol. Cancer Ther. 2007;6:2766–2776
  34. Nadeau PJ, Charette SJ, Landry J. REDOX reaction at ASK1-Cys250 is essential for activation of JNK and induction of apoptosis. Mol. Biol Cell. 2009;20:3628–3637
  35. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, et al. Bcl-2 undergoes phosphorylation by the c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac. J. Biol. Chem. 1997;272:25238–25242
  36. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J. Biol. Chem. 2000;275:322–327
  37. Milne DM, Campbell LE, Campbell DG, Meek DW. p53 Is phosphorylated in vitro and in vivo by an ultraviolet radiation induced protein kinase characteristic of the c-Jun kinase JNK1. J. Biol. Chem. 1995;270:5511–5518
  38. Bushmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 1997;21:2743–2754
  39. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J. Biol. Chem. 2002;277:43730–43734
  40. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16:68–377
  41. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 2008;60:261–310
  42. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer?. Cell Cycle. 2009;8:1168–1175
  43. Wang A, Rud J, Olson CM, Anguita J, Osborne BA. Phosphorylation of Nur77 by the MEK-ERK-RSK cascade induces mitochondrial translocation and apoptosis in T cells. J. Immunol. 2009;183:3268–3277

PII: S0304-3835(09)00630-2

doi: 10.1016/j.canlet.2009.10.008

Cancer Letters
Volume 291, Issue 2 , Pages 167-176 , 28 May 2010

Article Tools

* Image Usage & Resolution